Neuberger Berman Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Neuberger Berman Group’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$301K	Buy	5,816 +108	+2%	+$5.5K	﹤0.01%	1837
2025 Q4	$284K	Sell	5,708 -75	-1%	-$3.65K	﹤0.01%	1827
2025 Q3	$276K	Buy	+5,783	New	+$233K	﹤0.01%	1782
2017 Q4	–	Sell	-16,500	Closed	-$660K	–	1812
2017 Q3	$660K	Buy	+16,500	New	+$714K	﹤0.01%	1239
2016 Q4	–	Sell	-26,500	Closed	-$655K	–	1636
2016 Q3	$655K	Buy	26,500 +7,500	+39%	+$170K	﹤0.01%	1210
2016 Q2	$387K	Buy	+19,000	New	+$337K	﹤0.01%	1308

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group's SUPN Position: Q1 2026 in Review

Neuberger Berman Group increased its Supernus Pharmaceuticals (SUPN) stake by 1.9% in Q1 2026, buying an estimated $5.5K and bringing the position to 5,816 shares worth $301K. The position accounts for ﹤0.01% of the portfolio, ranked #1837.

Neuberger Berman Group first reported a position in SUPN in Q2 2016 and has held it in 6 quarters since. The position peaked at $660K in Q3 2017. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Neuberger Berman Group held 5,816 shares of Supernus Pharmaceuticals worth $301K as of Q1 2026.
Neuberger Berman Group bought 108 Supernus Pharmaceuticals shares in Q1 2026, an estimated $5.5K.
Supernus Pharmaceuticals made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #1837 holding.
Neuberger Berman Group first reported a position in Supernus Pharmaceuticals in Q2 2016 and has held it in 6 quarters since.
Neuberger Berman Group's Supernus Pharmaceuticals position peaked at $660K in Q3 2017.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.